FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.
What happened
FDA inspected Regenerative Processing Plant, LLC in Palm Harbor, FL, from June 20 to June 30, 2023. It found significant CGMP violations in the manufacture of Regener-Eyes PRO and LITE, which purport to be sterile and preservative-free multiple-dose eye products distributed nationwide. FDA also reviewed the firm's websites in August 2024 and found claims such as “Relieve Dryness of the Eye” and “combat dry eye-triggering hyperosmolarity,” leading to unapproved-new-drug and misbranding findings.
What FDA found
The Regener-Eyes products are unapproved new drugs and misbranded because no approved application is in effect and the labeling makes claims that are false or misleading.
FD&C Act §§ 505(a), 502(a), 502(ee) [21 U.S.C. §§ 355(a), 352(a), 352(ee)]The firm did not validate the sterile filling process; broth fill tests had contaminated units, did not incubate all filled units, and used broth without growth-promotion testing.
21 CFR 211.113(b)The firm lacked adequate environmental monitoring in the sterile processing area, including defined alert/action levels and growth-promotion testing for monitoring media.
21 CFR 211.42(c)(10)(iv)Stability studies did not support the labeled 24-month room-temperature storage for Regener-Eyes PRO, with failed objectives and pH outside the defined range.
21 CFR 211.166(a)The firm did not test the identity of components such as sodium chloride and glycerin, and batch records did not identify sodium chloride used in the tonicity solution.
21 CFR 211.84(d)(1); 211.188(b)(3)The firm had not validated cleaning and disinfection of the biosafety cabinets and cleanrooms, and it could not locate required records or reserve samples for the discontinued amniotic-fluid product.
21 CFR 211.42(c)(10)(v); 211.180(a); 211.170(b)
What FDA wants
FDA asks the firm to address the inadequate corrective actions, explain disposition of quarantined inventory, and say whether it will take additional voluntary actions for already distributed Regener-Eyes products. The letter does not state a response deadline.
Who should pay attention
- optometrists and eye clinics that dispense or recommend Regener-Eyes
- patients using Regener-Eyes eye drops
- companies selling sterile or OTC ophthalmic drug products
This is a summary. Read the original letter on fda.gov.